Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts

Acta Pharmacologica Sinica

Volumn 30, Issue 1, 2009, Pages 1-24

  Rao, Yuan James ^a   Xi, Lei ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac protection; Cell survival; Cyclic AMP; Cyclic GMP; Ischemia reperfusion injury; Myocardial contraction; Myocardial infarction; Phosphodiesterase inhibitors; Potassium channels; Signal transduction in cardiovascular system

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; AMRINONE; ATORVASTATIN; CARDIOTONIC AGENT; CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; DIGOXIN; DOBUTAMINE; ENOXIMONE; LOPRINONE; MILRINONE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NITRATE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PIMOBENDAN; ROFLUMILAST; ROLIPRAM; SILDENAFIL; ST THOMAS HOSPITAL SOLUTION; TADALAFIL; UDENAFIL; UNINDEXED DRUG; VARDENAFIL; VASOPRESSIN; CYCLIC NUCLEOTIDE; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ABDOMINAL DISCOMFORT; ASTHENIA; ASTHMA; CARDIOMYOPATHY; CELL PROTECTION; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; INOTROPISM; INTERMITTENT CLAUDICATION; LIVER FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; MITRAL VALVE STENOSIS; NAUSEA; NONHUMAN; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNCOPE; THROMBOCYTOPENIA; VOMITING; ANIMAL; CELL SURVIVAL; CYTOLOGY; HEART CONTRACTION; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL SURVIVAL; HUMANS; ISOENZYMES; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 64849108442     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.1     Document Type: Review

References (257)

1. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-27.
2. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007; 100: 489-501.
3. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58: 488-520.
4. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007; 21: 171-94.
5. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007; 99: 4A-23A.
6. Wang S, Cone J, Fong M, Yoshitake M, Kambayashi J, Liu Y. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermitent claudication. J Cardiovasc Pharmacol 2001; 38: 775-83.
7. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Hernandez M, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 1988; 238: 2-6.
8. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007; 144: 239-46.
9. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-61.
10. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702.
11. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 2004; 16 Suppl 1: S4-S7.
12. Zaccolo M, Movsesian MA. cAMP and cGMP signaling crosstalk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007; 100: 1569-78.
13. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006; 99: 816-28.
14. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) super-family: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-98.
15. Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phospho-diesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007; 100: 950-66.
16. Kass DA, Takimoto E, Nagayama T, Champion HC. Phospho-diesterase regulation of nitric oxide signaling. Cardiovasc Res 2007; 75: 303-14.
17. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007; 101: 1084-95.
18. Beavo JA, Houslay MD, Francis S (editors). Cyclic Nucleotide Phospho diesterases in Health and Disease. Boca Raton, FL: CRC Press; 2007.
19. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003; 93: 896-906.
20. Lohmann SM, Fischmeister R, Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol 1991; 86: 503-14.
21. Tomita H, Nazmy M, Kajimoto K, Yehia G, Molina CA, Sadoshima J. Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation. Circ Res 2003; 93: 12-22.
22. Booz GW. Puting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system. Hypertension 2005; 45: 341-6.
23. Sucharov CC. Beta-adrenergic pathways in human heart failure. Expert Rev Cardiovasc Ther 2007; 5: 119-24.
24. Movsesian MA. Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy. Cardiovasc Res 2004; 62: 450-9.
25. Cooper DM. Regulation and organization of adenylyl cyclases and cAMP. Biochem J 2003; 375: 517-29.
26. Shannon R, Chaudhry M. Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J 2006; 152: 842-50.
27. Denninger JW, Marletta MA. Guanylate cyclase and the NO/ cGMP signaling pathway. Biochim Biophys Acta 1999; 1411: 334-50.
28. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000; 86: 49-86.
29. 2+ in intact cardiac myocytes. Circ Res 1994; 74: 970-8.
30. Vila-Petroff MG, Younes A, Egan J, Lakata EG, Sollot SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999; 84: 1020-31.
31. Mohan P, Brutsaert DL, Paulus WJ, Sys SU. Myocardial contractile response to nitric oxide and cGMP. Circulation 1996; 93: 1223-9.
32. Kojda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 1996;78: 91-101.
33. Chesnais JM, Fischmeister R, Mery PF. Positive and negative inotropic effects of NO donors in atrial and ventricular fibres of the frog heart. J Physiol 1999; 518: 449-61.
34. Paolocci N, Ekelund UE, Isoda T, Ozaki M, Vandegaer K, Georgakopoulos D, et al. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol 2000; 279: H1982-H1988.
35. 2+ channels in the heart: overview of recent advances. Mol Cell Biochem 2003; 253: 3-13.
36. Kamp TJ, Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 2000; 87: 1095-102.
37. Wang Y, Wagner MB, Joyner RW, Kumar R. cGMP-dependent protein kinase mediates stimulation of L-type calcium current by cGMP in rabbit atrial cells. Cardiovasc Res 2000; 48: 310-22.
38. Xiao B, Zhong G, Obayashi M, Yang D, Chen K, Walsh MP, et al. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J 2006; 396: 7-16.
39. Zalk R, Lehnart SE, Marks AR. Modulation of the ryanodine receptor and intracellular calcium. Annu Rev Biochem 2007; 76: 367-85.
40. 2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 2005; 38: 291-302.
41. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003; 4: 566-77.
42. 2+ exchanger in failing pig myocytes. Circ Res 2003; 92: 897-903.
43. 2+ exchange in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 2005; 288: H2342-H2354.
44. 2+ exchanger. Role of phosphorylation. J Biol Chem 2006; 281: 7784-92.
45. al Hillawi E, Bhandari DG, Trayer HR, Trayer IP. The effects of phosphorylation of cardiac troponin-I on its interactions with actin and cardiac troponin-C. Eur J Biochem 1995; 228: 962-70.
46. Bilchick KC, Duncan JG, Ravi R, Takimoto E, Champion HC, Gao WD, et al. Heart failure-associated alterations in troponin I phosphorylation impair ventricular relaxation-afterload and force-frequency responses and systolic function. Am J Physiol Heart Circ Physiol 2007; 292: H318-25.
47. Hunlich M, Begin KJ, Gorga JA, Fishbaugher DE, LeWinter MM, VanBuren P. Protein kinase A mediated modulation of actomyosin kinetics. J Mol Cell Cardiol 2005; 38: 119-25.
48. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 2005; 66: 12-21.
49. Li MX, Wang X, Sykes BD. Structural based insights into the role of troponin in cardiac muscle pathophysiology. J Muscle Res Cell Motil 2004; 25: 559-79.
50. Messer AE, Jacques AM, Marston SB. Troponin phosphoryla tion and regulatory function in human heart muscle: Dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 2007; 42: 247-59.
51. Sakthivel S, Finley NL, Rosevear PR, Lorenz JN, Gulick J, Kim S, et al. In vivo and in vitro analysis of cardiac troponin I phosphorylation. J Biol Chem 2005; 280: 703-14.
52. Qin X, Zheng X, Qi H, Dou D, Raj JU, Gao Y. cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin- and nitric-oxide-induced relaxation in porcine coronary artery. Pflugers Arch 2007; 454: 913-23.
53. Kudej RK, Zhang XP, Ghaleh B, Huang CH, Jackson JB, Kudej AB, et al. Enhanced cAMP-induced nitric oxide-dependent coronary dilation during myocardial stunning in conscious pigs. Am J Physiol Heart Circ Physiol 2000; 279: H2967-H2974.
54. 2+ channel alpha1 subunit and reduced ischemia/ reperfusion injury. Circ Res 2006; 98: 403-11.
55. Gonzalez DR, Fernandez IC, Ordenes PP, Treuer AV, Eller G, Boric MP. Differential role of S-nitrosylation and the NO-cGMP-PKG pathway in cardiac contractility. Nitric Oxide 2008;18: 157-67.
56. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 2002; 277: 38072-8.
57. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 1997; 272: 6823-6.
58. Hambleton R, Krall J, Tikishvili E, Honeggar M, Ahmad F, Manganiello VC, et al. Isoforms of cyclic nucleotide phospho-diesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 2005; 280: 39168-74.
59. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 2001; 66: 241-77.
60. Patrucco E, Note A, Barberis L, Selvetella G, Maffei A, Brancaccio M, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004; 118: 375-87.
61. Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 2007; 19: 1765-71.
62. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002; 295: 1711-5.
63. Wen JF, Cui X, Jin JY, Kim SM, Kim SZ, Kim SH, et al. High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria. Circ Res 2004; 94: 936-43.
64. Kauffman RF, Crowe VG, Utterback BG, Robertson DW. LY195115: a potent, selective inhibitor of cyclic nucleotide phos pho diesterase located in the sarcoplasmic reticulum. Mol Pharmacol 1986; 30: 609-16.
65. Fischmeister R, Hartzell HC. Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells. Mol Pharmacol 1990; 38: 426-33.
66. Kirstein M, Rivet-Bastide M, Hatem S, Benardeau A, Mercadier JJ, Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 1995; 95: 794-802.
67. Frace AM, Mery PF, Fischmeister R, Hartzell HC. Rate-limiting steps in the beta-adrenergic stimulation of cardiac calcium current. J Gen Physiol 1993; 101: 337-53.
68. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 1993; 268: 26286-95.
69. 2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 1990; 345: 158-61.
70. Friis UG, Jensen BL, Sethi S, Andreasen D, Hansen PB, Skott O. Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. Circ Res 2002; 90: 996-1003.
71. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005; 111: 2469-76.
72. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 2005; 102: 14771-6.
73. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, et al. Selective inhibitor of platelet cyclic adenosine monophos phate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 1979; 211: 26-30.
74. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001; 19: 369-86.
75. Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure therapy - a silver bullet? J Am Anim Hosp Assoc 2006; 42: 90-3.
76. Zausig YA, Stowe DF, Zink W, Grube C, Martin E, Graf BM. A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts. Anesth Analg 2006; 102: 1646-52.
77. Osadchii OE, Woodiwiss AJ, Norton GR. Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adreno receptor activation. Pflugers Arch 2006; 452: 155-63.
78. Olson EM, Kim D, Smith TW, Marsh JD. Mechanism of the positive inotropic effect of milrinone in cultured embryonic chick ventricular cells. J Mol Cell Cardiol 1987; 19: 95-104.
79. Kajimoto K, Hagiwara N, Kasanuki H, Hosoda S. Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. Br J Pharmacol 1997; 121: 1549-56.
80. Sutko JL, Kenyon JL, Reeves JP. Effects of amrinone and milrinone on calcium influx into the myocardium. Circulation 1986; 73: III52-III58.
81. 2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol. Cardiovasc Drugs Ther 1999; 13: 105-13.
82. Alousi AA, Johnson DC. Pharmacology of the bipyridines: amrinone and milrinone. Circulation 1986; 73: III10-III24.
83. 2+ and related ions on the cardiac action of milrinone. J Cardiovasc Pharmacol 1988; 11: 591-600.
84. 2+ release. J Pharmacol Exp Ther 2004; 310: 761-73.
85. Holmberg SR, Williams AJ. Phosphodiesterase inhibitors and the cardiac sarcoplasmic reticulum calcium release channel: differential effects of milrinone and enoximone. Cardiovasc Res 1991; 25: 537-45.
86. 2+ uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 2000; 279: H1898-H1905.
87. Ghelardoni S, Frascarelli S, Carnicelli V, Ronca-Testoni S, Zucchi R. Modulation of cardiac sarcoplasmic reticulum calcium release by aenosine: a protein kinase C-dependent pathway. Mol Cell Biochem 2006; 288: 59-64.
88. Floreani M, Fossa P, Gessi S, Mosti L, Borea PA, Dorigo P. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endo genous adenosine, and inhibition of cardiac type III phospho diesterase. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 109-18.
89. Lochner A, Genade S, Tromp E, Opie L, Moolman J, Thomas S, et al. Role of cyclic nucleotide phosphodiesterases in ischemic preconditioning. Mol Cell Biochem 1998; 186: 169-75.
90. Lowe H, Jacobsohn E. Protection of the hypoxic myocardium by the bispyridine derivatives AWD 122-14 and milrinone: studies on isolated, working right rabbit hearts. Pharmazie 1992; 47: 452-5.
91. Fukutomi T, Satoh K, Ogoshi S, Ichihara K. Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs. Coron Artery Dis 2000; 11: 83-90.
92. Carceles MD, Aleixandre F, Fuente T, Lopez-Vidal J, Laorden ML. Effects of rolipram, pimobendan and zaprinast on ischaemiainduced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthe tized rat. Eur J Anaesthesiol 2003; 20: 205-11.
93. Zucchi R, Poddighe R, Mariani M, Ronca G. Effect of amrinone in the working rat heart: influence of ischaemic damage, adenosine and calcium. Drugs Exp Clin Res 1990; 16: 187-95.
94. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 2001; 104: 705-10.
95. Use T, Makita T, Ureshino H, Cho S, Yoshitomi O, Akiyama D, et al. Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine. Cardiovasc Drugs Ther 2006; 20: 327-34.
96. Papp JG, Pollesello P, Varro AF, Vegh AS. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther 2006; 11: 129-35.
97. Levijoki J, Pollesello P, Kaheinen P, Haikala H. Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol 2001; 419: 243-8.
98. Saltman AE, Gaudete GR, Levitsky S, Krukenkamp IB. Amrinone preconditioning in the isolated perfused rabbit heart. Ann Thorac Surg 2000; 70: 609-13.
99. Rechtman MP, Van der Zypp A, Majewski H. Amrinone reduces ischaemia-reperfusion injury in rat heart. Eur J Pharmacol 2000; 402: 255-62.
100. Nomura Y, Horimoto H, Mieno S, Nakahara K, Okawa H, Yoshida M, et al. Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction. Mol Cell Biochem 2003; 248: 179-84.
101. Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermitent claudication. J Cardiovasc Pharmacol 2000; 36: 351-60.
102. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, et al. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 2007; 21: 321-30.
103. Chanani NK, Cowan DB, Takeuchi K, Poutias DN, Garcia LM, del Nido PJ, et al. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling. Circulation 2002; 106: I284-9.
104. Besirli K, Burhani SM, Arslan C, Suzer O, Sayin AG. Effect of combining phosphodiesterase III inhibitors with St Thomas Hospital's solution used as transplantation preservative solution in isolated rat hearts. Transplant Proc 2006; 38: 1253-8.
105. Koksal C, Suzer O, Bozkurt AK, Koseoglu S. Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts. Acta Medica (Hradec Kralove) 2002; 45: 93-7.
106. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320: 677-83.
107. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
108. Cuffe MS, Califf RM, Adams KF, Jr., Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-7.
109. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003.
110. Maskin CS, Forman R, Klein NA, Sonnenblick EH, LeJemtel TH. Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. Am J Med 1982; 72: 113-8.
111. Wynne J, Malacoff RF, Benotti JR, Curfman GD, Grossman W, Holman BL, et al. Oral amrinone in refractory congestive heart failure. Am J Cardiol 1980; 45: 1245-9.
112. Benoti JR, Grossman W, Braunwald E, Carabello BA. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 1980; 62: 28-34.
113. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985; 71: 963-71.
114. DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984; 4: 855-66.
115. Retig G, Sen S, Frohlig G, Schieffer H, Bete L. Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial. Eur Heart J 1986; 7: 628-31.
116. Marcus RH, Raw K, Patel J, Mitha A, Sareli P. Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1107-12.
117. Rich MW, Woods WL, Davila-Roman VG, Morello PJ, Kurz H, Barbarash R, et al. A randomized comparison of intra venous amrinone versus dobutamine in older patients with decompensated congestive heart failure. J Am Geriatr Soc 1995; 43: 271-4.
118. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benoti J, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990; 82: 774-80.
119. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000; 36: 501-8.
120. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-31.
121. Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002; 66: 149-57.
122. Feneck RO. Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group. Am Heart J 1991; 121: 1995-9.
123. Doolan LA, Jones EF, Kalman J, Buxton BF, Tonkin AM. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 37-41.
124. Oztekin I, Yazici S, Oztekin DS, Goksel O, Issever H, Canik S. Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension. Yakugaku Zasshi 2007; 127: 375-83.
125. Kochi K, Kyo S, Yokote Y, Ueda K, Asano H, Koyanagi T, et al. The effect of milrinone for the shock patients after cardiac surgery. Kyobu Geka 1999; 52: 239-42.
126. Kikura M, Levy JH, Bailey JM, Shanewise JS, Michelsen LG, Sadel SM. A bolus dose of 1.5 mg/kg amrinone effectively improves low cardiac output state following separation from cardiopulmonary bypass in cardiac surgical patients. Acta Anaesthesiol Scand 1998; 42: 825-33.
127. Hamada Y, Kawachi K, Nakata T, Tsunooka N, Takano S, Kohtani T. Effects of a phosphodiesterase III inhibitor on circulating blood volume after cardiopulmonary bypass. Heart Vessels 2000; 15: 70-3.
128. Lewis KP, Appadurai IR, Pierce ET, Halpern EF, Bode RH, Jr. Prophylactic amrinone for weaning from cardiopulmonary bypass. Anaesthesia 2000; 55: 627-33.
129. Osadchii O, Norton G, Woodiwiss A. Inotropic responses to phosphodies terase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol 2005; 514: 201-8.
130. Sherry KM, Locke TJ. Use of milrinone in cardiac surgical patients. Cardiovasc Drugs Ther 1993; 7: 671-5.
131. Koyanagi T, Kyo S, Ouchi H, Asano H, Yokote Y, Omoto R. Clinical experience of milrinone as a pharmacological bridge to heart trans plantation. Jpn J Thorac Cardiovasc Surg 2000; 48: 460-3.
132. Palmaers T, Albrecht S, Heuser F, Leuthold C, Schuettler J, Schmitz B. Milrinone combined with vasopressin improves cardiac index after cardiopulmonary resuscitation in a pig model of myocardial infarction. Anesthesiology 2007; 106: 100-6.
133. Sandroni C, Cavallaro F, Caricato A, Scapigliati A, Fenici P, Antonelli M. Enoximone in cardiac arrest caused by propranolol: two case reports. Acta Anaesthesiol Scand 2006; 50: 759-61.
134. Richter W, Jin SL, Conti M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 2005; 388: 803-11.
135. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 1996; 271: 16526-34.
136. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005; 437: 574-8.
137. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, et al. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 2001; 276: 11189-98.
138. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123: 25-35.
139. Lehnart SE. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr Opin Pharmacol 2007; 7: 225-32.
140. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci USA 2006; 103: 511-8.
141. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, et al. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem 2003; 278: 49230-8.
142. Xiang Y, Naro F, Zoudilova M, Jin SL, Conti M, Kobilka B. Phosphodies terase 4D is required for beta2 adrenoceptor subtypespecific signaling in cardiac myocytes. Proc Natl Acad Sci USA 2005; 102: 909-14.
143. Lefkowitz RJ, Pierce KL, Luttrell LM. Dancing with different partners: protein kinase a phosphorylation of seven membranespanning receptors regulates their G protein-coupling specificity. Mol Pharmacol 2002; 62: 971-4.
144. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, et al. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 2005; 280: 33178-89.
145. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, et al. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 2003; 100: 940-5.
146. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 2004; 95: 67-75.
147. Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991; 40: 127-9.
148. Huang Z, Mancini JA. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem 2006; 13: 3253-62.
149. 2+ current in rat ventricular myocytes. Br J Pharmacol 1999; 127: 65-74.
150. Juan-Fita MJ, Vargas ML, Kaumann AJ, Hernandez Cascales J. Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 324-9.
151. Muller B, Lugnier C, Stoclet JC. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J Cardiovasc Pharmacol 1990; 16: 796-803.
152. Katano Y, Endoh M. Differential effects of Ro 20-1724 and isobutyl methylxanthine on the basal force of contraction and beta-adrenoceptor-mediated response in the rat ventricular myocardium. Biochem Biophys Res Commun 1990; 167: 123-9.
153. Shahid M, Nicholson CD. Comparison of cyclic nucleotide phosphodies terase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 698-705.
154. Herzer WA, Thomas NJ, Carcillo JA, Tofovic SP, Jackson EK. Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. J Cardiovasc Pharmacol 1998; 32: 769-76.
155. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987; 61: 539-47.
156. Simpson PJ, Schelm JA, Smallwood JK, Clay MP, Lindstrom TD. Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury. J Cardiovasc Pharmacol 1992; 19: 987-95.
157. McVey M, Perrone MH, Clark KL. Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anesthetized rats? Gen Pharmacol 1999; 32: 41-5.
158. Glover DK, Riou LM, Ruiz M, Sullivan GW, Linden J, Rieger JM, et al. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol 2005; 288: H1851-H1858.
159. Holbrook M, Coker SJ. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits. Br J Pharmacol 1991; 103: 1973-9.
160. Zussman BD, Benincosa LJ, Webber DM, Clark DJ, Cowley H, Kelly J, et al. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol 2001; 41: 950-8.
161. Zussman BD, Kelly J, Murdoch RD, Clark DJ, Mbchb, Schubert C, et al. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. Clin Ther 2001; 23: 921-31.
162. Bethke TD, Bohmer GM, Hermann R, Hauns B, Fux R, Morike K, et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phospho-diesterase 4 inhibitor. J Clin Pharmacol 2007; 47: 26-36.
163. Growcot EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 2006; 7: 9.
164. Dutta P, Ryan DE, Tabrizchi R. The influence of phospho-diesterase inhibitor, rolipram, on hemodynamics in lipopoly-saccharide-treated rats. Jpn J Pharmacol 2001; 85: 241-9.
165. Thomas NJ, Carcillo JA, Herzer WA, Mi Z, Tofovic SP, Jackson EK. Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats. Eur J Pharmacol 2003; 465: 133-9.
166. Mohamed HE, Asker ME, Ali SI, el Fatah TM. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol 2004; 56: 757-68.
167. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, Trong HL, Colbran JL, et al. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 1993; 268: 22863-73.
168. Reffelmann T, Kloner RA. Therapeutic potential of phospho-diesterase 5 inhibition for cardiovascular disease. Circulation 2003; 108: 239-44.
169. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238-48.
170. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001; 15: 1718-26.
171. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005; 280: 12944-55.
172. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007; 115: 2159-67.
173. Francis SH, Lincoln TM, Corbin JD. Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 1980; 255: 620-6.
174. Lin CS, Lau A, Tu R, Lue TF. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 2000; 268: 628-35.
175. Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal 2002; 14: 45-51.
176. Zoraghi R, Bessay EP, Corbin JD, Francis SH. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 2005; 280: 12051-63.
177. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 2003; 22: 469-78.
178. Turko IV, Francis SH, Corbin JD. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phospho-diesterase (PDE5) is required for its phosphorylation. Biochem J 1998; 329: 505-10.
179. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000; 267: 2760-7.
180. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310-7.
181. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005; 96: 100-9.
182. Muller B, Lugnier C, Stoclet JC. Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria. J Cardiovasc Pharmacol 1990; 15: 444-51.
183. 2+ current in single heart cells. Nature 1986; 323: 273-5.
184. 2+ channel current in human atrial myocytes. J Physiol 2001; 533: 329-40.
185. 2+ current in guinea-pig ventricular cells. J Physiol 1991; 443: 387-404.
186. Sugiyama A, Satoh Y, Shiina H, Takahara A, Yoneyama M, Hashimoto K. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 2001; 38: 940-6.
187. Piccirillo G, Nocco M, Lioneti M, Moise A, Naso C, Marigliano V, et al. Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002; 143: 703-10.
188. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005; 112: 2642-9.
189. Phillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, et al. Sympathetic activation by sildenafil. Circulation 2000; 102: 3068-73.
190. Cremers B, Scheler M, Maack C, Wendler O, Schafers HJ, Sudkamp M, et al. Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. J Cardiovasc Pharmacol 2003; 41: 734-43.
191. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C.
192. Corbin J, Rannels S, Neal D, Chang P, Grimes K, Beasley A, et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003; 19: 747-52.
193. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C.
194. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-6.
195. Sugiyama A, Takeuchi N, Saegusa Y, Sugita M, Hashimoto K. Molecular mechanisms of cardiostimulatory effects of sildenafil. Jpn J Pharmacol 2002; 88: 362-4.
196. Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000; 55: 146-50.
197. ATP channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007; 42: 453-8.
198. Sesti C, Florio V, Johnson EG, Kloner RA. The phospho-diesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007; 19: 55-61.
199. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, et al. Cardioprotection with phosphodiesterase-5 inhibition - a novel precondi tioning strategy. J Mol Cell Cardiol 2004; 36: 165-73.
200. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 2005; 42: 219-32.
201. Raja SG. Cardioprotection with sildenafil: implications for clinical practice. Curr Med Chem 2006; 13: 3155-64.
202. ATP channels in rabbits. Am J Physiol Heart Circ Physiol 2002; 283: H1263-H1269.
203. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 2005; 57: 22-7.
204. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003; 92: 595-7.
205. Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Diabetes abolishes sildenafil-induced preconditioning in dogs. FASEB J 2004; 18: A262.
206. Das S, Maulik N, Das DK, Kadowitz PJ, Bivalacqua TJ. Cardioprotec tion with sildenafil, a selective inhibitor of cyclic 3',5'-mono phosphate-specific phosphodiesterase 5. Drugs Exp Clin Res 2002; 28: 213-9.
207. + channels in sildenafil-induced late cardioprotection. J Mol Cell Cardiol 2008; 44: 105-13.
208. P channels in rabbits. J Mol Cell Cardiol 2006; 40: 405-11.
209. du Toit EF, Rossouw E, Salie R, Opie LH, Lochner A. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005; 19: 23-31.
210. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, et al. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 2006; 20: 27-36.
211. Nagy O, Hajnal A, Parrat JR, Vegh A. Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol 2004; 141: 549-51.
212. Das A, Xi L, Kukreja RC. Protein kinase G dependent cardio protec tive mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 2008; 283: 29572-85.
213. Das A, Ockaili R, Salloum F, Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 2004; 286: H1455-H1460.
214. Elrod JW, Greer JJ, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol 2007; 292: H342-H347.
215. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. J Am Coll Cardiol 2005; 46: 450-6.
216. Jamnicki-Abegg M, Weihrauch D, Chiari PC, Krolikowski JG, Pagel PS, Warltier DC, et al. Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardio protection. J Cardiovasc Pharmacol 2007; 50: 670-6.
217. Bischoff E. Vardenafil preclinical trial data: potency, pharmaco-dynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004; 16 Suppl 1: S34-S37.
218. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92: 37M-46M.
219. Traverse JH, Chen YJ, Du R, Bache RJ. Cyclic nucleotide phospho dies terase type 5 activity limits blood flow to hypo perfused myocardium during exercise. Circulation 2000; 102: 2997-3002.
220. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol 2001; 37: 286-92.
221. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phospho dies terase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107: 3230-5.
222. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78: 1207-13.
223. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hubler M, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108 Suppl 1: II167-II173.
224. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.
225. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.
226. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-96.
227. Kang KK, Ahn GJ, Sohn YS, Ahn BO, Kim WB. DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats. Arch Pharm Res 2003; 26: 612-9.
228. Kang KK, Ahn GJ, Sohn YS, Ahn BO, Kim WB. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J Int Med Res 2003; 31: 517-28.
229. Dias-Junior CA, Vieira TF, Moreno H Jr, Evora PR, Tanus-Santos JE. Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension. Pulm Pharmacol Ther 2005; 18: 181-6.
230. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-51.
231. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-40.
232. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336-9.
233. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005; 111: 742-6.
234. Chen Y, Traverse JH, Hou M, Li Y, Du R, Bache RJ. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2003; 284: H1513-H1520.
235. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007; 49: 1079-88.
236. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Belloti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097-103.
237. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005; 96: 1436-40.
238. Ferreira-Melo SE, Yugar-Toledo JC, Coelho OR, De Luca IM, Tanus-Santos JE, Hyslop S, et al. Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol 2006; 542: 141-7.
239. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phospho-diesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111: 1601-10.
240. Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci USA 2008; 105: 7028-33.
241. Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy. N Engl J Med 1999; 341: 700-1.
242. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 2005; 128: 3065-73.
243. Bode DC, Kanter JR, Brunton LL. Cellular distribution of phosphodies terase isoforms in rat cardiac tissue. Circ Res 1991; 68: 1070-9.
244. Georget M, Mateo P, Vandecasteele G, Lipskaia L, Defer N, Hanoune J, et al. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J 2003; 17: 1380-91.
245. Wu SN, Li HF, Chiang HT. Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem Pharmacol 2001; 61: 877-92.
246. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986; 35: 1743-51.
247. Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA. The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res 2005; 46: 494-503.
248. Mongillo M, Toccheti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/ cGMP-dependent pathway. Circ Res 2006; 98: 226-34.
249. Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Benardeau A, Mercadier JJ, et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997; 99: 2710-8.
250. Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 1995; 7: 733-8.
251. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004; 47: 1081-92.
252. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 2005; 105: 3569-76.
253. Chambers RJ, Abrams K, Garceau NY, Kamath AV, Manley CM, Lilley SC, et al. A new chemical tool for exploring the physiological function of the PDE2 isozyme. Bioorg Med Chem Lett 2006; 16: 307-10.
254. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59: 347-56.
255. Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I, Tosaki A, et al. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 2005; 46: 369-76.
256. Brunkhorst D, der Leyen H, Meyer W, Nigbur R, SchmidtSchumacher C, Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 575-83.
257. 1 receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol 2007; 43: 545-51.